A5078259199- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Research on Leishmaniasis Studies
- Nosocomial Infections in ICU
- Antibiotic Use and Resistance
- Trypanosoma species research and implications
- Pneumonia and Respiratory Infections
- Enterobacteriaceae and Cronobacter Research
- Animal Virus Infections Studies
- Dermatological diseases and infestations
- Biochemical and Molecular Research
- Healthcare cost, quality, practices
- Immunodeficiency and Autoimmune Disorders
- Viral Infections and Immunology Research
- Health Systems, Economic Evaluations, Quality of Life
- Child and Adolescent Health
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- SARS-CoV-2 and COVID-19 Research
- Neonatal skin health care
- Clostridium difficile and Clostridium perfringens research
- Hematological disorders and diagnostics
- Neonatal and Maternal Infections
Université Paris Cité
2024
Université Claude Bernard Lyon 1
2024
Assistance Publique – Hôpitaux de Paris
2024
Hôpital Cochin
2024
Centre de Recherche sur l'Inflammation
2024
Sorbonne Université
2024
Hôpital Saint Joseph
2024
Inserm
2024
Centre de Recherche des Cordeliers
2024
Hôpital Beaujon
2024
In a phase 3 trial, bulevirtide monotherapy led to virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy and peginterferon alfa-2a, particularly regard finite treatment, unclear.
Finite therapy of HBV/HDV co-infection with REP 2139-Ca and pegIFN has good long term safety is accompanied by high rates functional cure HDV, normalization liver function additional HBV. HBV inactivation / clearance cccDNA integrated DNA. The nucleic acid polymer 2139 inhibits assembly/secretion hepatitis B virus (HBV) subviral particles. Previously, pegylated interferon (pegIFN) in HBV/hepatitis delta (HDV) coinfection achieved HDV RNA surface antigen (HBsAg) loss/seroconversion the 301...
Abstract Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion. However, monotherapy with the nucleic acid polymer REP 2139-Ca is accompanied by rapid declines in both RNA. We used mathematical modeling estimate HDV-HBsAg-host parameters elucidate mode of action efficacy 12 treatment-naive HBV/HDV co-infected patients. The model...
Nucleic acid polymers block the assembly of hepatitis B virus (HBV) subviral particles, effectively preventing surface antigen (HBsAg) replenishment in circulation. polymer (NAP)-based combination therapy HBV infection or HBV/hepatitis D (HDV) co-infection is accompanied by HBsAg clearance and seroconversion, HDV-RNA co-infection, persistent functional cure (HBsAg < 0.05 IU/ml, HBV-DNA target not dected, normal alanine aminotransferase) HDV RNA. An analysis isoform changes during...
Analyzing the interplay among serum HBV DNA, HBsAg, anti-HBs, and alanine aminotransferase (ALT) during nucleic-acid polymer (NAP)-based therapy for chronic hepatitis B provides a unique opportunity to identify kinetic patterns associated with functional cure.All participants HBeAg-negative infection in REP 401 study (NCT02565719) first received 24 weeks of tenofovir-disoproxil-fumarate (TDF) monotherapy. The early triple group (n = 20) next 48 TDF+pegylated interferon-α2a (pegIFN)+NAPs. In...
Therapy with nucleic acid polymers (NAPs), tenofovir disoproxil fumarate (TDF), and pegylated interferon (pegIFN) achieve high rates of HBsAg loss/seroconversion functional cure in chronic hepatitis B virus (HBV) infection. The role surface antigen (HBsAg) seroconversion inactivation covalently closed circular DNA (cccDNA) establishing were examined. Archived serum from the REP 401 study was analyzed using Abbott ARCHITECT NEXT assay (Chicago, IL), research use–only assays for immune...
Abstract Treatment of HBV infection with nucleic acid polymers and pegIFN is accompanied by transaminase elevations in 95% participants. viral rebound, partial cure (HBV DNA < 2000 IU/mL, normal ALT) or functional target not detected, HBsAg <LLOQ, occurred 27%, 38% 35% Correlations between ALT, AST GGT elevations, virologic baseline, response during therapy therapeutic outcome were investigated. A retrospective analysis all 40 participants the REP 401 study (NCT02565719) included...
advantage of our HCV culture system in primary human adult hepatocytes (PHH), which, contrary to the widely used hepatocarcinoma-derived Huh-7 sublines, retain liver metabolism ethanol and secrete authentic VLDL LVP.METHODS: PHH were infected with strain JFH1 or a chimeric virus derived thereof treated increasing doses (0-100 mM) for 2 weeks.Cultures monitored genome replication (negative strand RT-qPCR), viral load (clinically test), production infectious (titration by focus-formation...
Results Acute HDV in both sexes has been observed: women – 7 (26.9%), men 19 (73.1%). Hepatitis D virus infection occurred through: surgical maneuvers 2 patients (7.7%), dental 5(19.2%), sexual 3 (11.5%) intrafamilial and undetermined way 14 (53.9%). The acute onset was 26 (100%), being manifested more frequently icteric form 21 (80.8%), than anicteric 5 (19.2%). In 12 (46.2%), occurs moderate (53.8%) severe form. includes asthenic, dyspeptic arthralgic syndrome. Biochemical investigations:...
Background Hepatitis B viral represents a pathology with severe impact on public health. Worldwide, approximately 350 million individuals are chronically infected hepatitis virus (HBV). HBV is the leading cause of cirrhosis globally. Once chronic infection established, 30% patients will develop cirrhosis, and one-quarter decompensated liver disease within 5 years. Cirrhosis also substantially increases risk for hepatocellular carcinoma (HCC).